According to a recent article on PMlive, "while harmonised regulatory approval processes have created synergies that decrease the workload of European payers and institutional stakeholders, the same may not be said for the case of health technology assessment (HTA)." With a diverse range of country specific HTA processes for new drug entrants, the growth of HTA across European healthcare systems has created a number of implications for the industry.
At HTA World Europe 2012, Jim Furniss, GfK highlighted this key point in his presentation on "The growth of HTA- Implications for the industry."
The presentation covers:
- The growth of Health Technology Assessment
- Recent developments in HTA
- Implications for the pharmaceutical industry
- Strategic considerations
Want to learn about the latest HTA requirements from different HTA authorities across Europe? Book now for HTA World Europe 2013, held this 4-5th December in London. The first early bird expires next Friday, 13th September to book now for the best available rates.
For more information, download the HTA brochure